| abstract |
The invention relates to polypeptide compositions that bind to CD20 antigen, especially human CD20 antigen. The polypeptide composistions have the biological activity of known anti-CD20 antibodies, such as 2B8 or Leu16, but show a reduced immunogenicity as compared with the non-modified molecules. The polypeptide compositions include chimeric antibodies, antibody fragments, and fusion proteins of an antibody or antibody fragment with a cytokine. |